The association of cancer with a clinical hypercoagulable state has been known for
over 140 years but continues to be an important clinical problem. Despite rapid changes
in cancer treatments, venous thromboembolism (VTE) remains associated with novel anti-cancer
regimens. These include lenalidomide in multiple myeloma, immunotherapy agents in
various solid tumors, cyclin dependent kinase inhibitors in breast cancer and anti-epidermal
growth factor receptor antibodies in colorectal cancers [
1
,
2
,
3
,
4
]. Arterial thromboembolism, although less well-studied, has also been associated with
multi-targeted tyrosine kinase inhibitors such as sorafenib and sunitinib as well
as immunotherapy [
[5]
,
[6]
].Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors.J Thromb Haemost. 2020; 18: 162-168
- Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.Ann Oncol. 2012; 23: 1672-1679
- Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis.Cancer. 2020;
- Venous thromboembolism in cancer patients receiving immunotherapy.Blood. 2018; 132: 2510
- Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.J Clin Oncol. 2010; 28: 2280-2285
- Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study.Eur J Cancer. 2019; 120: 122-131
- Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States.Clinicoecon Outcomes Res. 2013; 5: 101-108
Khorana AA, McCrae KR, Milentijevic D, et al. Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer. J Med Econ2020:1-7.
- Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update.J Clin Oncol. 2019; (JCO1901461)
- Management of venous thromboembolism in cancer patients: considerations about the clinical practice guideline update of the American society of clinical oncology.Eur J Int Med. 2020; 71: 4-7
- Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer.N Engl J Med. 2019; 380: 720-728
- Apixaban to prevent venous thromboembolism in patients with cancer.N Engl J Med. 2019; 380: 711-719
- Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial.Thromb Res. 2017; 151: 89-95
- A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score.Intern Emerg Med. 2012; 7: 291-292
- Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States.Cancer. 2020;
- Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial.J Thromb Haemost. 2020; 18: 411-421
- The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH.J Thromb Haemost. 2019; 17: 1772-1778
- Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.J Thromb Haemost. 2018; 16: 1891-1894
- 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.Lancet Oncol. 2019; 20: e566-ee81
Article info
Publication history
Published online: February 22, 2020
Accepted:
February 18,
2020
Received:
February 6,
2020
Identification
Copyright
© 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
